Toxicities of CAR T-Cell Therapy and Bispecific Antibodies

This chapter explores the toxicities linked to CAR T-cell therapy and bispecific antibodies through patient case studies, particularly focusing on older patients. It discusses the development of acute myeloid leukemia and myelodysplastic syndrome in patients receiving these therapies, emphasizing the role of prior treatments in these outcomes. Furthermore, it addresses management strategies for side effects like cytokine release syndrome and the ongoing need for monitoring in patients treated with these innovative therapies.